Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Nucleoside/nucleotide reverse transcriptase inhibitor drug interactions.

Yohan P Samarasinghe1, Marta Boffito, Giovanni Di Perri

  • 1PK Research-St. Stephen's Centre, Chelsea and Westminster Hospital, 369 Fulham Road, London SW10 9NH, UK.

Journal of HIV Therapy
|February 26, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The multifaceted antiretroviral coverage provided by BIC/FTC/TAF: a pharmacokinetic/pharmacodynamic revisitation.

Le infezioni in medicina·2026
Same author

The cerebrospinal fluid virome in people with HIV: links to neuroinflammation and cognition.

Frontiers in microbiology·2025
Same author

Extending follow-up visits in people with HIV (PWH) receiving bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) therapy: an expert opinion.

Le infezioni in medicina·2025
Same author

The cerebrospinal fluid virome in people with HIV: links to neuroinflammation and cognition.

bioRxiv : the preprint server for biology·2025
Same author

How Antiretroviral Drug Concentrations Could Be Affected by Oxidative Stress, Physical Capacities and Genetics: A Focus on Dolutegravir Treated Male PLWH.

Antioxidants (Basel, Switzerland)·2025
Same author

Effectiveness, safety, and patient-reported outcomes of bictegravir/emtricitabine/tenofovir alafenamide in routine clinical care in Italy: 12-Month results from the BICSTaR cohort.

International journal of STD & AIDS·2025

Nucleoside and nucleotide reverse transcriptase inhibitors are crucial for HIV therapy, often working synergistically. This review details their beneficial and detrimental interactions with other HIV drugs and non-HIV medications.

Area of Science:

  • Pharmacology
  • Infectious Diseases
  • Drug Interactions

Background:

  • Nucleoside and nucleotide reverse transcriptase inhibitors (NRTIs) form the cornerstone of modern antiretroviral therapy (ART).
  • Their efficacy in suppressing HIV replication relies on combination therapies, often leveraging synergistic interactions.
  • However, potential for adverse drug interactions exists within this class and with other antiretroviral agents and non-HIV drugs.

Purpose of the Study:

  • To comprehensively review clinically significant interactions involving nucleoside and nucleotide reverse transcriptase inhibitors.
  • To differentiate between beneficial (synergistic) and detrimental (antagonistic, pharmacokinetic, pharmacodynamic) interactions.
  • To provide clinicians with essential information for optimizing NRTI-based antiretroviral regimens.

Related Experiment Videos

Main Methods:

  • Systematic literature review of published studies on NRTI interactions.
  • Analysis of pharmacokinetic and pharmacodynamic data from clinical trials and observational studies.
  • Identification and categorization of clinically relevant drug-drug interactions (DDIs).

Main Results:

  • NRTIs demonstrate significant synergistic interactions, enhancing HIV suppression when combined appropriately.
  • Numerous detrimental pharmacokinetic interactions (e.g., altered absorption, metabolism, excretion) were identified.
  • Pharmacodynamic interactions, including additive toxicities and antagonistic effects, were also observed with various co-administered drugs.

Conclusions:

  • Understanding NRTI interactions is critical for effective HIV management and minimizing adverse events.
  • Clinicians must carefully consider potential DDIs when prescribing combination antiretroviral therapy.
  • Further research is warranted to elucidate complex interactions and guide personalized treatment strategies.